| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/15/2004 | WO2003039466A3 Method of treating estrogen responsive breast cancer |
| 01/15/2004 | WO2003023048A3 METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l) |
| 01/15/2004 | WO2003016467A3 Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass |
| 01/15/2004 | WO2003012048A3 Antigens of and antibodies to translocated molecules of microorganisms and uses thereof |
| 01/15/2004 | WO2003006059A9 Vegfr-1 antibodies to treat breast cancer |
| 01/15/2004 | WO2003004620A3 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/15/2004 | WO2002092854A3 Genes expressed in breast cancer as prognostic and therapeutic targets |
| 01/15/2004 | WO2002080966A8 Method for producing a vaccine containing autologous antibodies |
| 01/15/2004 | WO2002078526A3 Cancer-testis antigens |
| 01/15/2004 | WO2002066629A9 Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| 01/15/2004 | WO2002060935A8 A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences |
| 01/15/2004 | WO2002046364A8 Genes associated with mechanical stress, expression products therefrom, and uses thereof |
| 01/15/2004 | US20040010814 Comprises nucleotide sequences coding kinases for developing contraceptives and controlling sex determination in animals |
| 01/15/2004 | US20040010811 Mixture comprising modulator for cancer activity; anticarcinogenic agents; tumor diagnosis; immunotherapy |
| 01/15/2004 | US20040010134 Albumin fusion proteins |
| 01/15/2004 | US20040010132 53 human secreted proteins |
| 01/15/2004 | US20040010125 Human immunodeficiency viral glycoprotein (HIV) for diagnosis, prevention and treatment of viral infection; genetic vaccines |
| 01/15/2004 | US20040010124 CD16A binding proteins and use for the treatment of immune disorders |
| 01/15/2004 | US20040010002 Also identifying agents that are useful for alleviating and inhibiting lymphoproliferative disorders or inhibiting metastasis of lymphatic tumors |
| 01/15/2004 | US20040010001 Methods and compositions for modulating cell proliferation and cell death |
| 01/15/2004 | US20040009944 Methylated immunostimulatory oligonucleotides and methods of using the same |
| 01/15/2004 | US20040009943 Pathogen vaccines and methods for using the same |
| 01/15/2004 | US20040009942 Administering a polynucleotide having an immunostimulatory sequence comprising the sequence 5'-C, G-3'; a respiratory virus antigen is not administered |
| 01/15/2004 | US20040009941 Microspheres and adjuvants for DNA vaccine delivery |
| 01/15/2004 | US20040009939 Methods of enhancing immune induction involving MDA-7 |
| 01/15/2004 | US20040009937 Intranasal administration of an immunogenic composition of a microflora organism having an expression vector wherein said expression vector comprises a heterologous nucleic acid that encodes for an antigen. |
| 01/15/2004 | US20040009936 Vaccine and drug delivery by topical application of vectors and vector extracts |
| 01/15/2004 | US20040009906 Induction of antigen specific immunologic tolerance |
| 01/15/2004 | US20040009904 APL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies |
| 01/15/2004 | US20040009903 Macroaggregated albumin-polyethyleneimine (MAA-PEI) lung-targeted delivery of respiratory syncytial virus DNA vaccines |
| 01/15/2004 | US20040009897 Stabilized synthetic immunogen delivery system |
| 01/15/2004 | US20040009594 Propagating cytotoxic t lymphocytes from hemopoietic stem cells and using them for treating cancer; immunotherapy |
| 01/15/2004 | US20040009588 Comprises targeted adenoviral expression vector coding antitumor agent; gene therapy; gene expression inhibition |
| 01/15/2004 | US20040009546 Compositions and methods for inhibiting microbial adhesion |
| 01/15/2004 | US20040009508 RTVP based compositions and methods for the treatment of prostate cancer |
| 01/15/2004 | US20040009503 Diagnosing and treating an inflammatory syndrome with a mixture comprising antibodies and antisense RNA, specific inhibiting bind to enzyme, stimulating an immune response, vaccination |
| 01/15/2004 | US20040009502 Identification and tissue distribution of two novel spliced variants of the mouse LATS2 gene |
| 01/15/2004 | US20040009480 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 01/15/2004 | US20040009469 Polypeptides and polynucleotides useful in methods of inducing immune response against flaviviruses, including dengue viruses |
| 01/15/2004 | US20040009195 Modified sialic acid vaccines |
| 01/15/2004 | US20040009194 Methods, and compositions for a therapeutic antigen presenting cell vaccine for treatment of immunodeficiency virus |
| 01/15/2004 | US20040009193 Lipid bilayer membrane derived from a eukaryotic microorganism as an outer membrane |
| 01/15/2004 | US20040009191 Inactivated virulence genes |
| 01/15/2004 | US20040009188 Present invention relates to a polypeptide antigen which derives from the gp41 protein, and also to the use thereof for immunization against HIV-related infection |
| 01/15/2004 | US20040009187 Rotavirus subunit vaccine |
| 01/15/2004 | US20040009186 Immunogenic peptides |
| 01/15/2004 | US20040009185 Enhancing the immune response to an antigen by presensitzing with an inducing agent prior to immunizing with the agent and the antigen |
| 01/15/2004 | US20040009184 Recombinant intracellular pathogen immunogenic compositions and methods for use |
| 01/15/2004 | US20040009179 Mycoplasma gallisepticum formulation |
| 01/15/2004 | US20040009177 In particular, amino acid sequences in the respiratory syncytial vorus G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease |
| 01/15/2004 | US20040009172 Biweekly subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha in combination with another drug which is useful for treating the disorder |
| 01/15/2004 | US20040009171 Methods for the treatment of carcinoma |
| 01/15/2004 | US20040009169 Administration of agents for the treatment of inflammation |
| 01/15/2004 | US20040009166 Single chain antigen-binding polypeptides for polymer conjugation |
| 01/15/2004 | US20040009148 Compositions and methods for modifying toxic effects of proteinaceous compounds |
| 01/15/2004 | US20040009147 Administering mixtures of antibodies and tumor necrosis factors, immunosuppressants, antibiotics, antiinflammatory agents, cytokines, angiogenesis inhibitors or fibroblast growth factors; prophylaxis of graft versus host disease |
| 01/15/2004 | US20040009146 Administering mixtures of gene expression vectors comprising cytokines coding sequences, fragments, variants or peptides, to mammals, for prophylaxis of cancer |
| 01/15/2004 | US20040009125 First series of intranasal administration of E-selectin over period of two weeks, followed by a booster administration of E-selectin after at least two weeks from the first administration of E-selectin to minimize brain tissue damage |
| 01/15/2004 | CA2531280A1 Vaccines to induce mucosal immunity |
| 01/15/2004 | CA2509684A1 Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer |
| 01/15/2004 | CA2494508A1 Nucleic acid compositions for stimulating immune responses |
| 01/15/2004 | CA2492010A1 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 01/15/2004 | CA2491992A1 Animal protein free media for cultivation of cells |
| 01/15/2004 | CA2491947A1 The use of specified tcf target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which tcf/.beta.-catenin/wnt signalling plays a central role |
| 01/15/2004 | CA2491690A1 Plastid genetic engineering via somatic embryogenesis |
| 01/15/2004 | CA2491574A1 Angio-immunotherapy |
| 01/15/2004 | CA2491508A1 Hcv fusion proteins with modified ns3 domains |
| 01/15/2004 | CA2491474A1 Boroproline compound combination therapy |
| 01/15/2004 | CA2491466A1 Methods and compositions relating to isoleucine boroproline compounds |
| 01/15/2004 | CA2491321A1 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 01/15/2004 | CA2490983A1 Immunostimulation by chemically modified rna |
| 01/15/2004 | CA2490903A1 Compositions and methods for the detection of human t cell receptor variable family gene expression |
| 01/15/2004 | CA2490714A1 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | CA2489919A1 Liposomal vaccine |
| 01/15/2004 | CA2488885A1 Preparation based on an antibody directed against a tumor-associated glycosylation such as lewis structures |
| 01/14/2004 | EP1380651A2 Recombinant fowlpox virus with intact FPV-tk-gene |
| 01/14/2004 | EP1380644A1 The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
| 01/14/2004 | EP1380290A1 Cross-beta structure pathway and its therapeutic relevance |
| 01/14/2004 | EP1379873A2 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 01/14/2004 | EP1379695A2 New polynucleotides and polypeptides of the ifnalpha-21 gene |
| 01/14/2004 | EP1379672A2 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc) |
| 01/14/2004 | EP1379670A1 Activated dual specificity lymphocytes and their methods of use |
| 01/14/2004 | EP1379662A2 Sulfatases and methods of use thereof |
| 01/14/2004 | EP1379656A2 G-protein coupled receptor molecules and uses thereof |
| 01/14/2004 | EP1379654A2 Intracellular signaling molecules |
| 01/14/2004 | EP1379650A2 Preferred segments of neural thread protein and methods of using the same |
| 01/14/2004 | EP1379649A2 Calcium binding proteins |
| 01/14/2004 | EP1379638A2 Implantation serine proteinases |
| 01/14/2004 | EP1379637A2 Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon |
| 01/14/2004 | EP1379635A2 Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions |
| 01/14/2004 | EP1379630A2 Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
| 01/14/2004 | EP1379628A2 Kinases and phosphatases sequences, and use thereof |
| 01/14/2004 | EP1379557A2 Use of cd25 binding molecules in steroid-resistant patients |
| 01/14/2004 | EP1379556A1 Anti pilyrosporum ovale lgy and its uses |
| 01/14/2004 | EP1379552A1 Toll-like receptor 5 ligands and methods of use |
| 01/14/2004 | EP1379551A2 Adp-ribosylating bacterial toxins |
| 01/14/2004 | EP1379550A2 A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences |
| 01/14/2004 | EP1379535A2 Expression vectors able to elicit improved immune response and methods of using same |
| 01/14/2004 | EP1379282A2 Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders |
| 01/14/2004 | EP1379281A2 A helper dependent adenoviral vector system and methods for using the same |